R M Fielding
Overview
Explore the profile of R M Fielding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
BEKERSKY I, Fielding R, Dressler D, Kline S, Buell D, Walsh T
J Clin Pharmacol
. 2001 Sep;
41(9):963-71.
PMID: 11549101
Amphotericin B (AmB) in small unilamellar liposomes (AmBisome) provides higher plasma concentrations and greater safety than the conventional deoxycholate formulation. The authors compared the disposition of the liposome's drug and...
2.
3.
BEKERSKY I, Boswell G, HILES R, Fielding R, Buell D, Walsh T
Pharm Res
. 2001 Apr;
17(12):1494-502.
PMID: 11303959
Purpose: Amphotericin B in small, unilamellar liposomes (AmBisome) is safer and produces higher plasma concentrations than other formulations. Because liposomes may increase and prolong tissue exposures, the potential for drug...
4.
Fielding R, Moon-McDermott L, LEWIS R
J Drug Target
. 2000 Aug;
6(6):415-26.
PMID: 10937287
Amikacin in small, low-clearance liposomes (MiKasome) has prolonged plasma and tissue residence and in vivo activity against extracellular infections, including Klebsiella pneumonia and Pseudomonas endocarditis. Small liposomes may cross endothelial...
5.
BEKERSKY I, Boswell G, HILES R, Fielding R, Buell D, Walsh T
Pharm Res
. 1999 Nov;
16(11):1694-701.
PMID: 10571274
Purpose: Amphotericin B (AmB) in small, unilamellar liposomes (AmBisome) has an improved therapeutic index, and altered pharmacokinetics. The repeat-dose safety and toxicokinetic profiles of AmBisome were studied at clinically relevant...
6.
Fielding R, Moon-McDermott L, LEWIS R, Horner M
Antimicrob Agents Chemother
. 1999 Feb;
43(3):503-9.
PMID: 10049258
Liposomal aminoglycosides have been shown to have activity against intracellular infections, such as those caused by Mycobacterium avium. Amikacin in small, low-clearance liposomes (MiKasome) also has curative and prophylactic efficacies...
7.
Fielding R, LEWIS R, Moon-McDermott L
Pharm Res
. 1998 Dec;
15(11):1775-81.
PMID: 9834002
Purpose: Amikacin in small unilamellar liposomes (MiKasome) has prolonged plasma residence (half-life > 24hr) and sustained efficacy in Gram-negative infection models. Since low-clearance liposomes may be subject to a lower...
8.
Wang L, Fielding R, Smith P, Guo L
Pharm Res
. 1995 Feb;
12(2):275-83.
PMID: 7784345
The pharmacokinetic profiles of amphotericin B (AmB) after administration of Amphocil, an AmB/cholesteryl sulfate colloidal dispersion (ABCD) and the micellar AmB/deoxycholate (Fungizone) were compared after repeated dosing in rats. After...
9.
Rioux F, Petitclerc E, Audet R, Drapeau G, Fielding R, MARCEAU F
J Cardiovasc Pharmacol
. 1994 Aug;
24(2):229-37.
PMID: 7526054
A genetically engineered recombinant human hemoglobin (rHb1.1) was recently developed for use as a blood substitute (Nature 1992;356:258-60). Like other mammalian hemoglobin (Hb) molecules, it might bind and antagonize the...
10.
Wang L, Smith P, Anderson K, Fielding R
J Chromatogr
. 1992 Sep;
579(2):259-68.
PMID: 1429973
A sensitive and reproducible high-performance liquid chromatographic method was developed to assay ampherotericin B in plasma, blood, urine and various tissue samples. Amphotericin B was isolated from each sample matrix...